by Stacey B. Trooskin, Helen Reynolds, and Jay R. Kostman
Clin Infect Dis 2015 61: 1825-1830
6 pp. 188 kB
http://cid.oxfordjournals.org/content/61/12/1825.full.pdf+html
Several breakthrough hepatitis C drugs received Food and Drug Administration approval in 2014, with cure rates exceeding 90%. These drugs are being rationed, due to costs. The authors propose an AIDS Drug Assistance Program analogue and cost-control mechanisms to facilitate treatment.
(Visited 69 times, 1 visits today)